BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND MUC1, PEM, 4582, ENSG00000185499, PUM, MAM6, EMA, CD227, H23AG
961 results:

  • 1. Genomic characterization and detection of potential therapeutic targets for peritoneal mesothelioma in current practice.
    van Kooten JP; Dietz MV; Dubbink HJ; Verhoef C; Aerts JGJV; Madsen EVE; von der Thüsen JH
    Clin Exp Med; 2024 Apr; 24(1):80. PubMed ID: 38642130
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Target proteins-regulated DNA nanomachine-electroactive substance complexes enable separation-free electrochemical detection of clinical exosome.
    Zeng X; Wu C; Xiong Y; Zhan Z; Shen C; Lin F; Zhang J; Chen P
    Biosens Bioelectron; 2024 Jul; 256():116273. PubMed ID: 38621341
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeted therapeutic options in early and metastatic NSCLC-overview.
    Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
    Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Disease control in patients with non-small cell lung cancer using pemetrexed: Investigating the best treatment strategy.
    Takahara Y; Abe R; Sumito N; Tanaka T; Ishige Y; Shionoya I; Yamamura K; Nishiki K; Nojiri M; Kato R; Shinomiya S; Oikawa T
    Thorac Cancer; 2024 Apr; 15(12):987-993. PubMed ID: 38485287
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. [A case of immune-related gastroesophagitis with laryngopharyngitis caused by immune checkpoint inhibitors in nonsmall cell lung cancer].
    Oka Y; Hamano Y; Nakamura R; Mabuchi K; Ochi M; Yamaguchi Y; Okawara H; Okawara A; Kakinoki N; Kamoshida T
    Nihon Shokakibyo Gakkai Zasshi; 2024; 121(3):221-229. PubMed ID: 38462470
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. An Unusual Presentation of Choriocarcinoma in a Postmenopausal Woman: A case report.
    Zribi A; Mazroui RA; Sayani R; Burney IA
    Sultan Qaboos Univ Med J; 2024 Feb; 24(1):135-138. PubMed ID: 38434469
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Primary pulmonary myxoid sarcoma with EWSR1::CREB1 fusion: a literature review.
    Miao X; Chen J; Yang L; Lu H
    J Cancer Res Clin Oncol; 2024 Feb; 150(3):108. PubMed ID: 38421462
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Biphasic papillary (biphasic squamoid alveolar) renal cell carcinoma: a clinicopathologic and molecular study of 17 renal cell carcinomas including 10 papillary adenomas.
    Nova-Camacho LM; Acosta AM; Akgul M; Panizo A; Galea LA; Val-Carreres A; Talavera JA; Guerrero-Setas D; Martin-Arruti M; Ruiz I; García-Martos M; Sangoi AR
    Virchows Arch; 2024 Mar; 484(3):441-449. PubMed ID: 38388964
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Venous Thromboembolism in Peritoneal Mesothelioma: Uncovering the Hidden Risk.
    Bansal VV; Mitchell O; Bregio C; Witmer HDD; Dhiman A; Godley FA; Ong C; Berger Y; Reddy B; Churpek JE; Drazer MW; Eng OS; Kindler HL; Turaga KK
    Ann Surg Oncol; 2024 May; 31(5):3339-3349. PubMed ID: 38372861
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Ki-67 Proliferation Index Is Associated With Tumor Grade and Survival in Pleural Epithelioid Mesotheliomas.
    Galeano B; Smith CJ; Yi ES; Roden AC; Jenkins S; Capelle J; Kittle-Francis M; Mansfield AS; Aubry MC
    Am J Surg Pathol; 2024 May; 48(5):615-622. PubMed ID: 38369761
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. SP3-induced Timeless transcription contributes to cell growth of lung adenocarcinoma cells.
    Tian P; Du D; Yang L; Zhou N; Tao L
    PLoS One; 2024; 19(2):e0298295. PubMed ID: 38354174
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A novel lncRNA-hidden polypeptide regulates malignant phenotypes and pemetrexed sensitivity in A549 pulmonary adenocarcinoma cells.
    Han X; Chen L; Sun P; Wang X; Zhao Q; Liao L; Lou D; Zhou N; Wang Y
    Amino Acids; 2024 Feb; 56(1):15. PubMed ID: 38351332
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. GT-00AxIL15, a Novel Tumor-Targeted IL-15-Based Immunocytokine for the Treatment of TA-muc1-Positive Solid Tumors: Preclinical In Vitro and In Vivo Pharmacodynamics and Biodistribution Studies.
    Gellert J; Jäkel A; Danielczyk A; Goletz C; Lischke T; Flechner A; Dix L; Günzl A; Kehler P
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338686
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Dendritic cell vaccination in combination with erlotinib in a patient with inoperable lung adenocarcinoma: a case report.
    Kosumi T; Kobayashi M; Shimodaira S; Sugiyama H; Koido S
    J Med Case Rep; 2024 Feb; 18(1):88. PubMed ID: 38336778
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. muc1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma.
    Xu H; Du Z; Li Z; Liu X; Li X; Zhang X; Ma J
    Ann Med; 2024 Dec; 56(1):2313671. PubMed ID: 38325364
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Mucin-1-Targeted Chimeric Antigen Receptor T Cells Are Effective and Safe in Controlling Solid Tumors in Immunocompetent Host.
    Zhou R; Wu ST; Yazdanifar M; Williams C; Sanders A; Brouwer C; Maher J; Mukherjee P
    J Immunother; 2024 Apr; 47(3):77-88. PubMed ID: 38270462
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Report and literature review of four cases of EWSR1::NFATC2 round cell sarcoma.
    Liu L; Li L; Ding Y; Kong F; Mo W; Ye H; Shen D
    Diagn Pathol; 2024 Jan; 19(1):19. PubMed ID: 38254207
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Accessibility of clinical study reports supporting medicine approvals: a cross-sectional evaluation.
    Hopkins AM; Modi ND; Rockhold FW; Hoffmann T; Menz BD; Veroniki AA; McKinnon RA; Rowland A; Swain SM; Ross JS; Sorich MJ
    J Clin Epidemiol; 2024 Mar; 167():111263. PubMed ID: 38219810
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Potential of fluoropyrimidine to be an immunologically optimal partner of immune checkpoint inhibitors through inducing immunogenic cell death for thoracic malignancies.
    Kozai H; Ogino H; Mitsuhashi A; Nguyen NT; Tsukazaki Y; Yabuki Y; Ozaki R; Yoneda H; Sato S; Hanibuchi M; Shinohara T; Nokihara H; Nishioka Y
    Thorac Cancer; 2024 Feb; 15(5):369-378. PubMed ID: 38146645
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Selection of potential targets for stratifying congenital pulmonary airway malformation patients with molecular imaging: is muc1 the one?
    van Horik C; Zuidweg MJP; Boerema-de Munck A; Buscop-van Kempen M; Brosens E; Vahrmeijer AL; von der Thüsen JH; Wijnen RMH; Rottier RJ; Tummers WSFJ; Schnater JM
    Eur Respir Rev; 2023 Dec; 32(170):. PubMed ID: 38123235
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 49.